Welcome to
Издательство Атмосфера

· Журналы
· Книги
· О проекте

·Электронные версии книг издательства “Атмосфера” поступили в продажу

Издательство “Атмосфера” идет в ногу со временем и открывает на своем сайте раздел электронных версий своих книг. Теперь вы можете приобрести не только традиционную бумажную книгу в картонном переплете, но и .pdf-файл, снабженный гиперссылками на каждую главу издания. В электронной версии проще отыскать рисунок и таблицу. Чтобы обратиться к ним, достаточно нажать на ссылку на каждый из них. Исчезла зависимость от тиража – вы можете приобрести даже те бестселлеры, тираж которых уже разошелся, такие как “Саркоидоз” или “Заболевания органов дыхания при беременности”. Упростилось получение вами книг – в течение двух рабочих дней после оплаты требуемые файлы придут на ваш e-mail. Ну и наконец, цена – электронные версии наших книг гораздо дешевле, чем бумажные издания. Заказывайте электронные версии книг издательства “Атмосфера” на сайте, а также по телефону: (495) 730-63-51 и по e-mail: atm-press2012@yandex.ru



ИНТЕРНЕТ-МАГАЗИН
Издательство Атмосфера


Телефон издательства

  
Практическая пульмонология (ранее – "Атмосфера. Пульмонология и аллергология"): ISSN 2409-756X (Online), ISSN 2409-6636 (Print)
2018 / N 1

Биологические маркеры при хронической обструктивной болезни легких
Э.Х. Анаев

Список литературы
1. Dubrey S, Shah S, Hardman T, Sharma R. Sarcoidosis: the links between epidemiology and aetiology. Postgraduate Medical Journal 2014 Oct;90(1068):582-9.
2. Baughman RP, Lower EE. Treatment of sarcoidosis. Clinical Reviews in Allergy & Immunology 2015 Aug;49(1):79-92.
3. Statement on sarcoidosis. Joint Statement of the American Thoracic Society (ATS), the European Respiratory Society (ERS) and the World Association of Sarcoidosis and Other Granulomatous Disorders (WASOG) adopted by the ATS Board of Directors and by the ERS Executive Committee, February 1999. American Journal of Respiratory and Critical Care Medicine 1999 Aug;160(2):736-55.
4. Amber KT, Bloom R, Mrowietz U, Hertl M. TNF-α: a treatment target or cause of sarcoidosis? Journal of the European Academy of Dermatology and Venereology 2015 Nov;29(11):2104-11.
5. Özdemir L, Özdemir B. A prospective review of the results of patients treated and followed up for a diagnosis of sarcoidosis. Turkish Thoracic Journal 2018 Jan;19(1):1-6.
6. West SG. Current management of sarcoidosis I: pulmonary, cardiac, and neurologic manifestations. Current Opinion in Rheumatology 2018 Jan; doi: 10.1097/BOR.0000000000000489. [Epub ahead of print]
7. Boucly A, Cottin V, Nunes H, Jaïs X, Tazi A, Prévôt G, Reynaud-Gaubert M, Dromer C, Viacroze C, Horeau-Langlard D, Pison C, Bergot E, Traclet J, Weatherald J, Simonneau G, Valeyre D, Montani D, Humbert M, Sitbon O, Savale L. Management and long-term outcomes of sarcoidosis-associated pulmonary hypertension. The European Respiratory Journal 2017 Oct;50(4). pii: 1700465. doi: 10.1183/13993003.00465-2017. Print 2017 Oct.
8. Strookappe B, Elfferich M, Swigris J, Verschoof A, Veschakelen J, Knevel T, Drent M. Benefits of physical training in patients with idiopathic or end-stage sarcoidosis-related pulmonary fibrosis: a pilot study. Sarcoidosis, Vasculitis and Diffuse Lung Diseases 2015 Jan;32(1):43-52.
9. Hendriks C, Drent M, De Kleijn W, Elfferich M, Wijnen P, De Vries J. Everyday cognitive failure and depressive symptoms predict fatigue in sarcoidosis: a prospective follow-up study. Respiratory Medicine 2017 Nov; pii: S0954-6111(17)30382-7.
10. Brown F, Tanner LS. Lofgren syndrome. In: StatPearls [Internet]. Treasure Island, FL: StatPearls Publishing; 2018 Jan. Last update 2018 Feb 8.
11. Bhalla AS, Das A, Naranje P, Goyal A, Guleria R, Khilnani GC. Dilemma of diagnosing thoracic sarcoidosis in tuberculosis endemic regions: an imaging-based approach. Part 1. Indian Journal of Radiology and Imaging 2017 Oct-Dec;27(4):369-79.
12. Oskuei A, Hicks L, Ghaffar H, Hoffstein V. Sarcoidosis-lymphoma syndrome: a diagnostic dilemma. BMJ Case Reports 2017 Dec: pii: bcr-2017-220065. doi: 10.1136/bcr-2017-220065.
13. Springer-Wanner C, Brauns T. Ocular sarcoidosis. Zeitschrift für Rheumatologie 2017 Jun;76(5):391-7.
14. Elikowski W, Małek-Elikowska M, Świerkocki K, Wróblewski D, Bolewski A, Janus M. Utility of left ventricular longitudinal strain in the diagnosis and treatment monitoring of cardiac sarcoidosis. Polish Archives of Internal Medicine 2018 Feb;128(2):126-8.
15. Maskery MP, Cooper PN, Pace A. Neurosarcoidosis associated with intracerebral haemorrhage: a challenge in diagnosis and management. Practical Neurology 2018. pii: practneurol-2017-001794. doi: 10.1136/practneurol-2017-001794. [Epub ahead of print].
16. Kieszko R, Krawczyk P, Michnar M, Chocholska S, Milanowski J. The yield of endobronchial biopsy in pulmonary sarcoidosis: connection between spirometric impairment and lymphocyte subpopulations in bronchoalveolar lavage fluid. Respiration 2004 Jan-Feb;71(1):72-6.
17. Valeyre D, Bernaudin JF, Jeny F, Duchemann B, Freynet O, Planès C, Kambouchner M, Nunes H. Pulmonary sarcoidosis. Clinics In Chest Medicine 2015 Dec;36(4):631-41.
18. Чучалин А.Г., Визель А.А., Илькович М.М., Авдеев С.Н., Амиров Н.Б., Баранова О.П., Борисов С. Е., Визель И.Ю., Ловачева О.В., Овсянников Н.В., Петров Д.В., Романов В.В., Самсонова М.В., Соловьева И.П., Соловьева И.П., Степанян И.Э., Тюрин И.Е., Черняев А.Л., Шмелев Е.И., Шмелева Н.М. Диагностика и лечение саркоидоза: резюме федеральных согласительных клинических рекомендаций. Часть 1: Классификация, этиопатогенез, клиника. Вестник современной клинической медицины 2014;7(4):62-70.
19. Broos CE, Wapenaar M, Looman CWN, In 't Veen JCCM3 van den Toorn LM, Overbeek MJ, Grootenboers MJJH, Heller R, Mostard RL, Poell LHC, Hoogsteden HC, Kool M, Wijsenbeek MS, van den Blink B. Daily home spirometry to detect early steroid treatment effects in newly treated pulmonary sarcoidosis. The European Respiratory Journal 2018 Jan;51(1). pii: 1702089. doi: 10.1183/13993003.02089-2017. Print 2018 Jan.
20. Чучалин А.Г., Айсанов З.Р., Чикина С.Ю., Черняк А.В., Калманова Е.Н. Федеральные клинические рекомендации Российского респираторного общества по использованию метода спирометрии. Пульмонология 2014;6:11-23.
21. Jones PW, Beeh KM, Chapman KR, Decramer M, Mahler DA, Wedzicha JA. Minimal clinically important differences in pharmacological trials. American Journal of Respiratory and Critical Care Medicine 2014 Feb;189(3):250-5.
22. Чучалин А.Г., Авдеев С.Н., Айсанов З.Р., Белевский А.С., Демура С.А., Илькович М.М., Коган Е.А., Самсонова М.В., Сперанская А.А., Тюрин И.Е., Черняев А.Л., Черняк Б.А., Черник А.В., Шмелев Е.И. Идиопатический легочный фиброз. Клинические рекомендации. Российское Респираторное общество; 2016. 44 с. Доступно по: www.spulmo.ru Ссылка активна на 31.05.2018.
23. Визель И.Ю. Саркоидоз в Республике Татарстан: эффективность диагностики и лечения, анализ отдаленных результатов: Автореф. дис. … докт. мед. наук. Москва, 2017. 48 с.
24. Broos CE, Poell LHC, Looman CWN, In 't Veen JCCM, Grootenboers MJJH, Heller R6, van den Toorn LM, Wapenaar M, Hoogsteden HC, Kool M, Wijsenbeek MS, van den Blink B. No evidence found for an association between prednisone dose and FVC change in newly-treated pulmonary sarcoidosis. Respiratory Medicine 2017 Oct; pii: S0954-6111(17)30361-X. doi: 10.1016/j.rmed.2017.10.022. [Epub ahead of print].
25. Jones NP, Tsierkezou L, Patton N. Lymphopenia as a predictor of sarcoidosis in patients with uveitis. British Journal of Ophthalmology 2016 Jan; pii: bjophthalmol-2015-307455. doi: 10.1136/bjophthalmol-2015-307455. Epub 2016 Jan 4.
26. Бекетов В.Д., Лебедева М.В., Мухин Н.А., Попова Е.Н., Серова А.Г., Соломка В.А., Кондрашов А.В., Пономарев А.Б., Бровко М.Ю. Клиническое значение определения сурфактантных протеинов A и D в оценке активности саркоидоза. Фарматека 2017;14(347):52-6.
27. Schupp JC, Freitag-Wolf S, Bargagli E. Mihailović-Vučinić V, Rottoli P, Grubanovic A, Müller A, Jochens A, Tittmann L, Schnerch J, Olivieri C, Fischer A, Jovanovic D, Filipovic S, Videnovic-Ivanovic J, Bresser P, Jonkers R, O’Reilly K, Ho LP, Gaede KI, Zabel P, Dubaniewicz A, Marshall B, Kieszko R, Milanowski J, Günther A, Weihrich A, Petrek M, Kolek V, Keane MP, O’Beirne S, Donnelly S, Haraldsdottir SO, Jorundsdottir KB, Costabel U, Bonella F, Wallaert B, Grah C, Peroš-Golubičić T, Luisetti M, Kadija Z, Pabst S, Grohé C, Strausz J, Vašáková M, Sterclova M, Millar A, Homolka J, Slováková A, Kendrick Y, Crawshaw A, Wuyts W, Spencer L, Pfeifer M, Valeyre D, Poletti V, Wirtz H, Prasse A, Schreiber S, Krawczak M, Müller-Quernheim J. Phenotypes of organ involvement in sarcoidosis. The European Respiratory Journal 2018 Jan;51(1): pii: 1700991. doi: 10.1183/13993003.00991-2017. Print 2018 Jan.
28. Pereira CA, Dornfeld MC, Baughman R, Judson MA. Clinical phenotypes in sarcoidosis. Current Opinion in Pulmonary Medicine 2014 Sep;20(5):496-502.
29. Culver DA, Baughman RP. It’s time to evolve from Scadding: phenotyping sarcoidosis. The European Respiratory Journal 2018 Jan;51(1 ). pii: 1800050. doi: 10.1183/13993003.00050-2018. Print 2018 Jan.
30. Федеральные клинические рекомендации по диагностике и лечению саркоидоза. Российское респираторное общество. 2016. Доступно по: www.spulmo.ru Ссылка активна на 31.05.2018.

References
1. Lange P, Halpin DM, O’Donnell DE, MacNee W. Diagnosis, assessment, and phenotyping of COPD: beyond FEV₁. International Journal of Chronic Obstructive Pulmonary Disease 2016 Feb;11 Spec Iss:3-12.
2. Fischer BM, Pavlisko E, Voynow JA. Pathogenic triad in COPD: oxidative stress, protease-antiprotease imbalance, and inflammation. International Journal of Chronic Obstructive Pulmonary Disease 2011;6:413-21.
3. Dahl M, Nordestgaard BG. Markers of early disease and prognosis in COPD. International Journal of Chronic Obstructive Pulmonary Disease 2009;4:157-67.
4. Leung JM, Sin DD. Biomarkers in airway diseases. Canadian Respiratory Journal 2013 May-Jun;20(3):180-2.
5. Gerritsen WB, Asin J, Zanen P, van den Bosch JM, Haas FJ. Markers of inflammation and oxidative stress in exacerbated chronic obstructive pulmonary disease patients. Respiratory Medicine 2005 Jan;99(1):84-90.
6. Koczulla AR, Noeske S, Herr C, Koepke J, Jörres RA, Nell C, Schmid S, Vogelmeier C, Bals R. Alpha-1 antitrypsin is elevated in exhaled breath condensate and serum in exacerbated COPD patients. Respiratory Medicine 2012 Jan;106(1):120-6.
7. Hurst JR, Donaldson GC, Perera WR, Wilkinson TM, Bilello JA, Hagan GW, Vessey RS, Wedzicha JA. Use of plasma biomarkers at exacerbation of chronic obstructive pulmonary disease. American Journal of Respiratory and Critical Care Medicine 2006 Oct;174(8):867-74.
8. Papaioannou AI, Mazioti A, Kiropoulos T, Tsilioni I, Koutsokera A, Tanou K, Nikoulis DJ, Georgoulias P, Zakynthinos E, Gourgoulianis KI, Kostikas K. Systemic and airway inflammation and the presence of emphysema in patients with COPD. Respiratory Medicine 2010 Feb;104(2):275-82.
9. Dickens JA, Miller BE, Edwards LD, Silverman EK, Lomas DA, Tal-Singer R. Evaluation of COPD Longitudinally to Identify Surrogate Endpoints (ECLIPSE) study investigators. COPD association and repeatability of blood biomarkers in the ECLIPSE cohort. Respiratory Research 2011 Nov;12:146-55.
10. Sng JJ, Prazakova S, Thomas PS, Herbert C. MMP-8, MMP-9 and neutrophil elastase in peripheral blood and exhaled breath condensate in COPD. COPD 2017 Apr;14(2):238-44.
11. Duvoix A, Dickens J, Haq I, Mannino D, Miller B, Tal-Singer R, Lomas DA. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax 2013 Jul;68(7):670-6.
12. Hurst JR, Vestbo J, Anzueto A, Locantore N, Müllerova H, Tal-Singer R, Miller B, Lomas DA, Agusti A, Macnee W, Calverley P, Rennard S, Wouters EF, Wedzicha JA; Evaluation of COPD Longitudinally to Identify Predictive Surrogate Endpoints (ECLIPSE) Investigators. Susceptibility to exacerbation in chronic obstructive pulmonary disease. The New England Journal of Medicine 2010 Sep;363(12):1128-38.
13. Engström G, Segelstorm N, Ekberg-Aronsson M, Nilsson PM, Lindgärde F, Löfdahl CG. Plasma markers of inflammation and incidence of hospitalisations for COPD: results from a population-based cohort study. Thorax 2009 Mar;64(3):211-5.
14. Montaño M, Sansores RH, Becerril C, Cisneros J, González-Avila G, Sommer B, Ochoa L, Herrera I, Ramírez-Venegas A, Ramos C. FEV1 inversely correlates with metalloproteinases 1, 7, 9 and CRP in COPD by biomass smoke exposure. Respiratory Research 2014 Jun;15:74-80.
15. Man SF, Xing L, Connett JE, Anthonisen NR, Wise RA, Tashkin DP, Zhang X, Vessey R, Walker TG, Celli BR, Sin DD. Circulating fibronectin to C-reactive protein ratio and mortality: a biomarker in COPD? The European Respiratory Journal 2008 Dec;32(6):1451-7.
16. Kelly E, Owen CA, Pinto-Plata V, Celli BR. The role of systemic inflammatory biomarkers to predict mortality in chronic obstructive pulmonary disease. Expert Review of Respiratory Medicine 2013 Feb;7(1):57-64.
17. D’Armiento JM, Scharf SM, Roth MD, Connett JE, Ghio A, Sternberg D, Goldin JG, Louis TA, Mao JT, O’Connor GT, Ramsdell JW, Ries AL, Schluger NW, Sciurba FC, Skeans MA, Voelker H, Walter RE, Wendt CH, Weinmann GG, Wise RA, Foronjy RF. Eosinophil and T cell markers predict functional decline in COPD patients. Respiratory Research 2009 Nov;10:113-25.
18. Bon JM, Leader JK, Weissfeld JL, Coxson HO, Zheng B, Branch RA, Kondragunta V, Lee JS, Zhang Y, Choi AM, Lokshin AE, Kaminski N, Gur D, Sciurba FC. The influence of radiographic phenotype and smoking status on peripheral blood biomarker patterns in chronic obstructive pulmonary disease. PLoS One 2009 Aug;4(8):e6865. doi: 10.1371/journal.pone.0006865.
19. Cazzolla M, Novelli G. Biomarkers in COPD. Pulmonary Pharmacology & Therapeutics 2010 Dec; 23(6):493-500.
20. Shaw JG, Vaughan A, Dent AG, O’Hare PE, Gon F, Bowman RV, Fong KM, Yang IA. Biomarkers of progression of chronic obstructive pulmonary disease (COPD). Journal of Thoracic Disease 2014 Nov;6(11):1532-47.
21. Faner R, Tal-Singer R, Riley JH, Celli B, Vestbo J, MacNee W, Bakke P, Calverley PM, Coxson H, Crim C, Edwards LD, Locantore N, Lomas DA, Miller BE, Rennard SI, Wouters EF, Yates JC, Silverman EK, Agusti A; ECLIPSE Study Investigators. Lessons from ECLIPSE: a review of COPD biomarkers. Thorax 2014 Jul;69(7):666-72.
22. Stockley RA. Biomarkers in chronic obstructive pulmonary disease: confusing or useful? International Journal of Chronic Obstructive Pulmonary Disease 2014 Feb;9:163-77.
23. Barnes PJ. The cytokine network in chronic obstructive pulmonary disease. American Journal of Respiratory Cell and Molecular Biology 2009 Dec;41(6):631-8.
24. Comandini A, Rogliani P, Nunziata A, Cazzola M, Curradi G, Saltini C. Biomarkers of lung damage associated with tobacco smoke in induced sputum. Respiratory Medicine 2009 Nov;103(11):1592-613.
25. Hacievliyagil SS, Mutlu LC, Temel I. Airway inflammatory markers in chronic obstructive pulmonary disease patients and healthy smokers. Nigerian Journal of Clinical Practice 2013 Jan-Mar;16(1):76-81.
26. Sapey E, Ahmad A, Bayley D, Newbold P, Snell N, Rugman P, Stockley RA. Imbalances between interleukin-1 and tumor necrosis factor agonists and antagonists in stable COPD. Journal of Clinical Immunology 2009 Jul;29(4):508-16.
27. Koutsokera A, Kostikas K, Nicod LP, Fitting JW. Pulmonary biomarkers in COPD exacerbations: a systematic review. Respiratory Research 2013 Oct;14:111.
28. Ravi AK, Khurana S, Lemon J, Plumb J, Booth G, Healy L, Catley M, Vestbo J, Singh D. Increased levels of soluble interleukin-6 receptor and CCL3 in COPD sputum. Respiratory Research 2014 Sep;15:103-12.
29. Costa C, Rufino R, Traves SL, Lapa E Silva JR, Barnes PJ, Donnelly LE. CXCR3 and CCR5 chemokines in induced sputum from patients with COPD. Chest 2008 Jan;133(1):26-33.
30. Traves SL, Donnelly LE. Th17 cells in airway diseases. Current Molecular Medicine 2008 Aug;8(5):416-26.
31. Rovina N, Dima E, Gerassimou C, Kollintza A, Gratziou C, Roussos C. Interleukin-18 in induced sputum: association with lung function in chronic obstructive pulmonary disease. Respiratory Medicine 2009 Jul;103(7):1056-62.
32. Zanini A, Chetta A, Imperatori AS, Spanevello A, Olivieri D. The role of the bronchial microvasculature in the airway remodelling in asthma and COPD. Respiratory Medicine 2010 Sep;11(1):132-42.
33. Zhu A, Ge D, Zhang J, Teng Y, Yuan C, Huang M, Adcock IM, Barnes PJ, Yao X. Sputum myeloperoxidase in chronic obstructive pulmonary disease. European Journal of Medical Research 2014 Mar;19:12-22.
34. Kinnula VL, Ilumets H, Myllärniemi M, Sovijärvi A, Rytilä P. 8-Isoprostane as a marker of oxidative stress in nonsymptomatic cigarette smokers and COPD. The European Respiratory Journal 2007 Jan;29(1):51-5.
35. Antus B. Oxidative stress markers in sputum. Oxidative Medicine and Cellular Longevity 2016;2016:2930434.
36. Ilumets H, Rytilä P, Demedts I, Brusselle GG, Sovijärvi A, Myllärniemi M, Sorsa T, Kinnula VL. Matrix metalloproteinases -8, -9 and -12 in smokers and patients with stage 0 COPD. International Journal of Chronic Obstructive Pulmonary Disease 2007 Oct;2(3):369-79.
37. Pandey KC, De S, Mishra PK. Role of proteases in chronic obstructive pulmonary disease. Frontiers in Pharmacology 2017 Aug;8:512.
38. Paone G, Conti V, Leone A, Schmid G, Puglisi G, Giannunzio G, Terzano C. Human neutrophil peptides sputum levels in symptomatic smokers and COPD patients. European Review for Medical and Pharmacological Sciences 2011 May;15(5):556-62.
39. Tufvesson E, Ekberg M, Bjermer L. Inflammatory biomarkers in sputum predict COPD exacerbations. Lung 2013 Aug;191(4):413-16.
40. Cazzola M, MacNee W, Martinez FJ, Rabe KF, Franciosi LG, Barnes PJ, Brusasco V, Burge PS, Calverley PM, Celli BR, Jones PW, Mahler DA, Make B, Miravitlles M, Page CP, Palange P, Parr D, Pistolesi M, Rennard SI, Rutten-van Mölken MP, Stockley R, Sullivan SD, Wedzicha JA, Wouters EF; American Thoracic Society; European Respiratory Society Task Force on outcomes of COPD. Outcomes for COPD pharmacological trials: from lung function to biomarkers. The European Respiratory Journal 2008 Feb;31(2):416-69.
41. Drost EM, Skwarski KM, Sauleda J, Soler N, Roca J, Agusti A, MacNee W. Oxidative stress and airway inflammation in severe exacerbations of COPD. Thorax 2005 Apr;60(4):293-300.
42. Rouhani F, Paone G, Smith NK, Krein P, Barnes P, Brantly ML. Lung neutrophil burden correlates with increased pro-inflammatory cytokines and decreased lung function in individuals with alpha(1)-antitrypsin deficiency. Chest 2000 May;117(5 Suppl 1):250S-1S.
43. Paone G, Wada A, Stevens LA, Matin A, Hirayama T, Levine RL, Moss J. ADP ribosylation of human neutrophil peptide-1 regulates its biological properties. Proceedings of the National Academy of Sciences of the United States of America 2002 Jun;99(12):8231-5.
44. Miller M, Ramsdell J, Friedman PJ, Cho JY, Renvall M, Broide DH. Computed tomographic scan-diagnosed chronic obstructive pulmonary disease-emphysema: eotaxin-1 is associated with bronchodilator response and extent of emphysema. Journal of Allergy and Clinical Immunology 2007 Nov;120(5):1118-25.
45. Paone G, Leone A, Batzella S, Conti V, Belli F, De Marchis L, Mannocci A, Schmid G, Terzano C. Use of discriminant analysis in assessing pulmonary function worsening in patients with sarcoidosis by a panel of inflammatory biomarkers. Inflammation Research 2013 Mar;62(3):325-32.
46. Csanky E, Rühl R, Scholtz B, Vasko A, Takacs L, Hempel WM. Lipid metabolite levels of prostaglandin D2 and eicosapentaenoic acid recovered from bronchoalveolar lavage fluid correlate with lung function of chronic obstructive pulmonary disease patients and controls. Electrophoresis 2009 Apr;30(7):1228-34.
47. Antczak A, Piotrowski W, Marczak J, Ciebiada M, Gorski P, Barnes PJ. Correlation between eicosanoids in bronchoalveolar lavage fluid and in exhaled breath condensate. Disease Markers 2011;30(5):213-20.
48. Comandini A, Marzano V, Curradi G, Federici G, Urbani A, Saltini C. Markers of anti-oxidant response in tobacco smoke exposed subjects: a data-mining review. Pulmonary Pharmacology & Therapeutics 2010 Jun;23(6):482-92.
49. Montuschi P, Kharitonov SA, Barnes PJ. Exhaled carbon monoxide and nitric oxide in COPD. Chest 2001 Aug;120(2):496-501.
50. Liu J, Sandrini A, Thurston MC, Yates DH, Thomas PS. Nitric oxide and exhaled breath nitrite/nitrates in chronic obstructive pulmonary disease patients. Respiration 2007;74(6):617-23.
51. Ferreira IM, Hazari MS, Gutierrez C, Zamel N, Chapman KR. Exhaled nitric oxide and hydrogen peroxide in patients with chronic obstructive pulmonary disease: effect of inhaled beclomethasone. American Journal of Respiratory and Critical Care Medicine 2001 Sep;164(6):1012-5.
52. Dragonieri S, Schot R, Mertens BJ, Le Cessie S, Gauw SA, Spanevello A, Resta O, Willard NP, Vink TJ, Rabe KF, Bel EH, Sterk PJ. An electronic nose in the discrimination of patients with asthma and controls. Journal of Allergy and Clinical Immunology 2007 Oct;120(4):856-62.
53. Fens N, Zwinderman AH, van der Schee MP, de Nijs SB, Dijkers E, Roldaan AC, Cheung D, Bel EH, Sterk PJ. Exhaled breath profiling enables discrimination of chronic obstructive pulmonary disease and asthma. American Journal of Respiratory and Critical Care Medicine 2009 Dec;180(11):1076-82.
54. Anaev EKh, Chuchalin AG. Exhaled air condensate in the diagnosis and evaluation of the effectiveness of treatment of respiratory diseases. Pulmonology 2006;4:12-20 (In Russian).
55. Antus B, Barta I, Kullmann T, Lazar Z, Valyon M, Horvath I, Csiszer E. Assessment of exhaled breath condensate pH in exacerbations of asthma and chronic obstructive pulmonary disease: a longitudinal study. American Journal of Respiratory and Critical Care Medicine 2010 Dec;182(12):1492-7.
56. Kostikas K, Papatheodorou G, Ganas K, Psathakis K, Panagou P, Loukides S. pH in expired breath condensate of patients with inflammatory airway diseases. American Journal of Respiratory and Critical Care Medicine 2002 May;165(10):1364-70.
57. Horvath I, Hunt J, Barnes PJ, Alving K, Antczak A, Baraldi E, Becher G, van Beurden WJ, Corradi M, Dekhuijzen R, Dweik RA, Dwyer T, Effros R, Erzurum S, Gaston B, Gessner C, Greening A, Ho LP, Hohlfeld J, Jöbsis Q, Laskowski D, Loukides S, Marlin D, Montuschi P, Olin AC, Redington AE, Reinhold P, van Rensen EL, Rubinstein I, Silkoff P, Toren K, Vass G, Vogelberg C, Wirtz H; ATS/ERS Task Force on Exhaled Breath Condensate. Exhaled breath condensate: methodological recommendations and unresolved questions. The European Respiratory Journal 2005 Sep;26(3):523-48.
58. Kostikas K, Papatheodorou G, Psathakis K. Panagou P, Loukides S. Oxidative stress in expired breath condensate of patients with COPD. Chest 2003 Oct;124(4):1373-80.
59. Kasielski M, Nowak D. Long-term administration of N-acetylcysteine decreases hydrogen peroxide exhalation in subjects with chronic obstructive pulmonary disease. Respiratory Medicine 2001 Jun;95(6):448-56.
60. Gessner C, Hammerschmidt S, Kuhn H, Hoheisel G, Gillissen A, Sack U, Wirtz H. Breath condensate nitrite correlates with hyperinflation in chronic obstructive pulmonary disease. Respiratory Medicine 2007 Nov;101(11):2271-8.
61. Corradi M, Montuschi P, Donnelly LE, Pesci A, Kharitonov SA, Barnes PJ. Increased nitrosothiols in exhaled breath condensate in inflammatory airway diseases. American Journal of Respiratory and Critical Care Medicine 2001 Mar;163(4):854-8.
62. Montuschi P, Macagno F, Parente P, Valente S, Lauriola L, Ciappi G, Kharitonov SA, Barnes PJ, Ciabattoni G. Effects of cyclo-oxygenase inhibition on exhaled eicosanoids in patients with COPD. Thorax 2005 Oct;60(10):827-33.
63. Antczak A, Ciebiada M, Pietras T, Piotrowski WJ, Kurmanowska Z, Górski P. Exhaled eicosanoids and biomarkers of oxidative stress in exacerbation of chronic obstructive pulmonary disease. Archives of Medical Science 2012 May;8(2):277-85.
64. Biernacki WA, Kharitonov SA, Barnes PJ. Increased leukotriene B4 and 8-isoprostane in exhaled breath condensate of patients with exacerbations of COPD. Thorax 2003 Apr;58(4):294-8.
65. Montuschi P, Collins JV, Ciabattoni G, Lazzeri N, Corradi M, Kharitonov SA, Barnes PJ. Exhaled 8-isoprostane as an in vivo biomarker of lung oxidative stress in patients with COPD and healthy smokers. American Journal of Respiratory and Critical Care Medicine 2000 Sep;162(3 Pt 1):1175-7.
66. Ko FW, Lau CY, Leung TF, Wong GW, Lam CW, Hui DS. Exhaled breath condensate levels of 8-isoprostane, growth related oncogene alpha and monocyte chemoattractant protein-1 in patients with chronic obstructive pulmonary disease. Respiratory Medicine 2006 Apr;100(4):630-8.
67. Rodionov AA, Revelsky AI, Revelsky IA, Anokhina TN, Anaev EKh. Determination of semivolatile organic compounds in exhaled breath condensate by gas chromatography-mass spectrometry. Journal of Analytical Chemistry 2014 Dec;69(14):1330-6.
68. Anokhina TN, Anaev EKh, Chuchalin AG, Revelskiy A, Rodionov AA, Revelskiy IA, Alexeev DV, Kudryavtsev VB. Metabolomic approach in the diagnosis of astma and COPD. Medline.ru 2011;12:1266-77 (In Russian).
69. Lin JL, Bonnichsen MH, Nogeh EU, Raftery MJ, Thomas PS. Proteomics in detection and monitoring of asthma and smoking-related lung diseases. Expert Review of Proteomics 2010 Jun;7(3):361-72.
70. Pelaia G, Terracciano R, Vatrella A, Gallelli L, Busceti MT, Calabrese C, Stellato C, Savino R, Maselli R. Application of proteomics and peptidomics to COPD. BioMed Research International 2014;2014:764581.
71. Anaev EKh, Fedorchenko KYu, Kushaeva ME, Ryabokon AM, Kononikhin AS, Barmin VV, Pikin OV, Popov IA, Nikolaev EN, Varfolomeev SD, Chuchalin AG. Diagnosis of respiratory diseases using the proteomic analysis of exhaled breath condensate. Pulmonology 2017;27(2):187-97 (In Russian).
72. Gessner C, Scheibe R, Wötzel M, Hammerschmidt S, Kuhn H, Engelmann L, Hoheisel G, Gillissen A, Sack U, Wirtz H. Exhaled breath condensate cytokine patterns in chronic obstructive pulmonary disease. Respiratory Medicine 2005 Oct;99(10):1229-40.
73. Ko FW, Leung TF, Wong GW, Ngai J, To KW, Ng S, Hui DS. Measurement of tumor necrosis factor-alpha, leukotriene B4, and interleukin 8 in the exhaled breath condensate in patients with acute exacerbations of chronic obstructive pulmonary disease. International Journal of Chronic Obstructive Pulmonary Disease 2009;4:79-86.
74. Garey KW, Neuhauser MM, Robbins RA, Danziger LH, Rubinstein I. Markers of inflammation in exhaled breath condensate of young healthy smokers. Chest 2004 Jan;125(1):22-6.
75. Antus B, Harnasi G, Drozdovszky O, Barta I. Monitoring oxidative stress during chronic obstructive pulmonary disease exacerbations using malondialdehyde. Respirology 2014 Jan;19(1):74-9.
76. Tateosian NL, Costa MJ, Guerrieri D, Barro A, Mazzei JA, Eduardo Chuluyan H. Inflammatory mediators in exhaled breath condensate of healthy donors and exacerbated COPD patients. Cytokine 2012 Jun;58(3):361-7.
77. Esther CR, Lazaar AL, Bordonali E, Qaqish B, Boucher RC. Elevated airway purines in COPD. Chest 2011 Oct;140(4):954-60.
  

[ Содержание выпуска N 1 | Выпуски журнала | Список журналов ]